Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review
Authors Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L, Yang L
Received 16 January 2016
Accepted for publication 7 May 2016
Published 29 June 2016 Volume 2016:9 Pages 3917—3923
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Quansong Xia,1 Juan Xu,2 Huoying Chen,3 Yanzhang Gao,1 Feili Gong,3 Liya Hu,1 Li Yang1
1Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University, 2The People’s Hospital of Guandu District, Kunming, 3Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Background: HMGB1 has been overexpressed in the tissues or serum of patients with non-small-cell lung cancer (NSCLC) in several studies. However, the results remain inconsistent.
Objective: The aim of this study was to perform a meta-analysis to investigate the relationship between elevated level of HMGB1 and NSCLC.
Methods: Associated studies were included, and the pooled risk difference and mean difference (MD) together with 95% confidence interval (CI) were calculated.
Results: A total of ten relevant studies on HMGB1 expression were included in this meta-analysis. The pooled results suggested that the expression of HMGB1 in NSCLC tissues was notably higher than those in corresponding nontumor normal tissues by using immunohistochemistry (risk difference =0.38, 95% CI: 0.28–0.48, Z=7.67, P<0.00001, I2=0%), Western blot (MD =0.27, 95% CI: 0.06–0.47, Z=2.57, P<0.01), or real-time polymerase chain reaction (MD =15.15, 95% CI: 14.8–15.5, Z=2.08, P=0.04). Serum HMGB1 levels were similarly significantly higher in patients with NSCLC than those in healthy controls. The pooled MDs of HMGB1 in patients with NSCLC compared with healthy controls were 17.54 with 95% CI: 10.99–24.09, Z=5.25, P<0.00001. Two of the included studies were fully reviewed without performing meta-analysis due to the different detection methods used. The protein level of HMGB1 in patients with NSCLC of tumor, nodes, and metastasis (TNM) stages III–IV was higher than that of TNM stages I–II (P<0.047 and P<0.001, respectively).
Conclusion: The expression levels of HMGB1 in both tissues and serum of patients with NSCLC were statistically higher than those of normal lung samples, which indicated that elevated levels of HMGB1 can reveal changes that correlated with disease progression, or even the risk of NSCLC disease progression. The elevated level of HMGB1 could also be considered as a potential biomarker for the diagnosis of patients with NSCLC.
Keywords: HMGB1, non-small-cell lung cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]